User login
Credit: NIAID
SAN FRANCISCO—CTL019, a chimeric antigen receptor (CAR) T cell targeting CD19, is not the only CAR in the production line.
Investigators at the National Cancer Institute in Bethesda, Maryland, and Memorial Sloan Kettering Cancer Center (MSKCC) in New York City are also pursuing CAR T-cell therapy.
These groups are using a retroviral platform to transduce the T cells rather than a lentiviral one, as is the case with CTL019.
Investigators reported progress to date on these makes of CARs at the 2014 ASH Annual Meeting.
Daniel W. Lee III, MD, of the National Cancer Institute, reported on a phase 1 study of CD19 CAR T cells in children and young adults with CD19+ acute lymphoblastic leukemia or non-Hodgkin lymphoma.
And Jae H. Park, MD, of MSKCC, presented data from a trial of JCAR015—autologous T cells genetically modified to express a 19-28z CAR targeting CD19—in patients with B-cell acute lymphoblastic leukemia.
The study is sponsored by MSKCC, but JCAR015 is a product of Juno Therapeutics. 
Credit: NIAID
SAN FRANCISCO—CTL019, a chimeric antigen receptor (CAR) T cell targeting CD19, is not the only CAR in the production line.
Investigators at the National Cancer Institute in Bethesda, Maryland, and Memorial Sloan Kettering Cancer Center (MSKCC) in New York City are also pursuing CAR T-cell therapy.
These groups are using a retroviral platform to transduce the T cells rather than a lentiviral one, as is the case with CTL019.
Investigators reported progress to date on these makes of CARs at the 2014 ASH Annual Meeting.
Daniel W. Lee III, MD, of the National Cancer Institute, reported on a phase 1 study of CD19 CAR T cells in children and young adults with CD19+ acute lymphoblastic leukemia or non-Hodgkin lymphoma.
And Jae H. Park, MD, of MSKCC, presented data from a trial of JCAR015—autologous T cells genetically modified to express a 19-28z CAR targeting CD19—in patients with B-cell acute lymphoblastic leukemia.
The study is sponsored by MSKCC, but JCAR015 is a product of Juno Therapeutics.
Credit: NIAID
SAN FRANCISCO—CTL019, a chimeric antigen receptor (CAR) T cell targeting CD19, is not the only CAR in the production line.
Investigators at the National Cancer Institute in Bethesda, Maryland, and Memorial Sloan Kettering Cancer Center (MSKCC) in New York City are also pursuing CAR T-cell therapy.
These groups are using a retroviral platform to transduce the T cells rather than a lentiviral one, as is the case with CTL019.
Investigators reported progress to date on these makes of CARs at the 2014 ASH Annual Meeting.
Daniel W. Lee III, MD, of the National Cancer Institute, reported on a phase 1 study of CD19 CAR T cells in children and young adults with CD19+ acute lymphoblastic leukemia or non-Hodgkin lymphoma.
And Jae H. Park, MD, of MSKCC, presented data from a trial of JCAR015—autologous T cells genetically modified to express a 19-28z CAR targeting CD19—in patients with B-cell acute lymphoblastic leukemia.
The study is sponsored by MSKCC, but JCAR015 is a product of Juno Therapeutics.